(Q43294341)

18 November 2017

title

Effect of treatment on weight gain and metabolic abnormalities in patients with first-episode psychosis (English)

1 reference

18 November 2017

1 reference

1 reference

3

Mythily Subramaniam

1 reference

18 November 2017

Swapna Verma

1

1 reference

18 November 2017

Alvin Liew

series ordinal

2

1 reference

18 November 2017

Lye Yin Poon

series ordinal

4

1 reference

18 November 2017

language of work or name

1 reference

1 September 2009

1 reference

Australian and New Zealand Journal of Psychiatry

18 November 2017

published in

1 reference

18 November 2017

volume

43

1 reference

18 November 2017

issue

9

1 reference

18 November 2017

page(s)

812-817

1 reference

Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Obesity as a risk factor for antipsychotic noncompliance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Weight gain in first-episode psychosis over three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

A comparison of risperidone-induced weight gain across the age span

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

New onset diabetes and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

Changes in body mass index for individuals with and without schizophrenia, 1987–1996

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00048670903107609

10.1080/00048670903107609

21 January 2018

Identifiers

DOI

1 reference

18 November 2017

1 reference